Patents Examined by Anne-Marie Falk
  • Patent number: 8476070
    Abstract: Well-defined, xeno-free culture media which comprise a TGF-beta isoform or the chimera formed between IL6 and the soluble IL6 receptor (IL6RIL6), which are capable of maintaining stem cells, and particularly, human embryonic stem cells, in an undifferentiated state are provided. Also provided are cell cultures comprising the culture media and the stem cells and methods of expanding and deriving embryonic stem cells in such well-defined, xeno-free culture media. In addition, the present invention provides methods of differentiating ESCs or EBs formed therefrom for the generation of lineage specific cells.
    Type: Grant
    Filed: August 29, 2006
    Date of Patent: July 2, 2013
    Assignee: Technion Research & Development Foundation Limited
    Inventors: Michal Amit, Joseph Itskovitz-Eldor
  • Patent number: 8445279
    Abstract: Facing no ethical obstacle and easily to be isolated, multipotent concretely mesenchymal stem cells (MSCs) are one of the most powerful tools in reconstructive medicine. Here the inventors introduced 3D multicelluar spheroids culture construction based on photolithography and micropatterning techniques to improve multipotent differentiation efficiency of MSCs to adult cells. This invention, the 3D spheroid cultured construction for MSCs, leads to great improve of the differentiation efficiency. This invention relates to a cultured cell construct comprising a support; at least one island on the support; a hydrophilic and cytophobic substance applied on the surface of said support so as to encircle the island; and a spheroid which is derived from MSCs, said spheroid being in contact with the island.
    Type: Grant
    Filed: October 21, 2008
    Date of Patent: May 21, 2013
    Assignee: Transparent Inc.
    Inventors: Wenjie Wang, Keiji Itaka, Shinsuke Ohba, Nobuhiro Nishiyama, Ung-il Chung, Yuichi Yamasaki, Kazunori Kataoka
  • Patent number: 8431767
    Abstract: Transgenic immunodeficient non-human animals according to embodiments of the present invention are described which include in their genome a nucleic acid encoding xenogeneic Stem Cell Factor operably linked to a promoter. Administration of xenogeneic hematopoetic stem cells to the inventive transgenic animals results in engraftment of the xenogeneic hematopoetic stem cells and xenogeneic leukocytes are produced in the animals, without conditioning such as without conditioning by irradiation and without conditioning by a radiomimetic agent.
    Type: Grant
    Filed: November 9, 2010
    Date of Patent: April 30, 2013
    Assignees: The Jackson Laboratory, University of Massachusetts Medical School
    Inventors: Leonard D. Shultz, Dale L. Greiner
  • Patent number: 8389250
    Abstract: A method of producing methionine, derivatives or precursors thereof comprising culturing a microorganism modified to enhance production of cysteine in a culture medium comprising a source of carbon and a source of sulfur and recovering methionine from the culture medium. A microorganism for fermentative production of methionine or its derivatives in which production of methionine or derivatives thereof, wherein the microorganism enhances production of cysteine.
    Type: Grant
    Filed: January 4, 2006
    Date of Patent: March 5, 2013
    Assignee: Metabolic Explorer
    Inventors: Rainer Figge, Fabien Lux, Céline Raynaud, Michel Chateau, Philippe Soucaille
  • Patent number: 8372643
    Abstract: There is provided a method of culturing a stem cell on extracellular matrix extracted from support cells and in a stem cell culture medium comprising medium conditioned by the support cells.
    Type: Grant
    Filed: December 5, 2008
    Date of Patent: February 12, 2013
    Assignee: Agency for Science, Technology and Research
    Inventors: Jackie Y. Ying, Andrew Chwee Aun Wan, Karthikeyan Narayanan, Karl M. Schumacher
  • Patent number: 8367406
    Abstract: Pluripotent cells that are immunopositive for both the neural progenitor marker nestin and a pluripotent cell marker are provided. The cells exhibit rapid doubling times and can be maintained in vitro for extended periods. Also provided are cell cultures containing the pluripotent cells, a method of transplanting human pluripotent cells to a host, and a method of reducing seizure activity in a subject. These pluripotent cells, when transplanted into the ventricle of a host animal, migrate to the site of damage and adopt a suitably corrective phenotype, resulting in both structural and functional restoration.
    Type: Grant
    Filed: July 20, 2009
    Date of Patent: February 5, 2013
    Assignee: Celavie Biosciences, LLC
    Inventor: Oleg V. Kopyov
  • Patent number: 8337812
    Abstract: It is intended to provide an agent for regulating axon extension during neuranagenesis by regulating ephrin-Eph receptor signaling mechanisms and to provide a mouse having abnormal ephrin-Eph receptor signaling mechanisms. The present invention relates to a regulator of axon extension, comprising an agent for promoting or suppressing the function of ?-chimerin, and to a miffy (mfy) mouse derived from a B6 strain, which displays autosomal recessive inheritance of an abnormal walking trait exhibiting a hopping gait with left-right synchronized movement of limbs and has mutation in an ?-chimerin gene.
    Type: Grant
    Filed: August 21, 2008
    Date of Patent: December 25, 2012
    Assignee: RIKEN
    Inventors: Takuji Iwasato, Shigeyoshi Itohara, Ryosuke Takahashi, Haruhisa Inoue
  • Patent number: 8338175
    Abstract: The present disclosure describes a tissue system with conjunctival cells, including conjunctival stem cells. The conjunctival tissue system is derived from isolated tissue comprising conjunctival cells, and is suitable for restoring ocular surface impairments, particularly those that result from damaged or diseased conjunctiva. The tissue system is generated using a simple single medium culture scheme, and a support material, such as human amniotic membrane. The conjunctival tissue system generate is suitable for transplantation to treat the ocular surface of an eye of a subject that is damaged or diseased.
    Type: Grant
    Filed: February 23, 2007
    Date of Patent: December 25, 2012
    Assignee: Reliance Life Sciences Pvt. Ltd.
    Inventors: Kashyap Subhadra Devi, Kishore Reddy, Viraf Vasania
  • Patent number: 8337833
    Abstract: Methods of causing an improvement in central nervous system function are provided. The methods include administering an aliquot of stem cells to the patient, the cells being derived from blood, e.g., umbilical cord blood. In some cases a growth factor is administered with the cells.
    Type: Grant
    Filed: May 11, 2010
    Date of Patent: December 25, 2012
    Assignees: The General Hospital Corp., ViaCord, LLC
    Inventors: Morey Kraus, Seth Finklestein, Paul Clark
  • Patent number: 8309352
    Abstract: The present invention relates to the use of umbilical cord blood cells from a donor or patient to provide neural cells which may be used in transplantation. The isolated cells according to the present invention may be used to effect autologous and allogeneic transplantation and repair of neural tissue, in particular, tissue of the brain and spinal cord and to treat neurodegenerative diseases of the brain and spinal cord.
    Type: Grant
    Filed: November 9, 2006
    Date of Patent: November 13, 2012
    Assignee: University of South Florida
    Inventors: Paul Sanberg, Juan Sanchez-Ramos, Alison Willing, Daniel D. Richard
  • Patent number: 8304237
    Abstract: The invention relates to a method for cultivating biologic cells (1), wherein cells (1) are grown on a substrate (10) having a plurality of substrate openings (11), and wherein cell aggregates (2) are formed, including groups of cells (1) that span the substrate openings (11). A separation of the cell aggregates (2) from the substrate (10) by extracting the cell aggregates (2) from the substrate openings (11) can be provided. The invention further relates to a cell-cultivating device (100), including a substrate (10) having a plurality of substrate openings (11) and cell aggregates (2) including groups of cells (1) that span the substrate openings (11). The cell aggregates (2) are particularly used in high throughput tests with biologically active substances or in methods of tissue cultivation.
    Type: Grant
    Filed: June 13, 2008
    Date of Patent: November 6, 2012
    Assignee: Fraunhofer-Gesellschaft zur Foerderung der Angewandten Forschung e.V.
    Inventors: Charli Kruse, Sandra Danner
  • Patent number: 8263822
    Abstract: Disclosed are a composition for inhibiting the expression of GA733-2 or for detecting GA733-2, which comprises TREM-2 gene or protein, a transgenic animal containing same, and a method using the same.
    Type: Grant
    Filed: February 18, 2009
    Date of Patent: September 11, 2012
    Assignee: GLO Biotech
    Inventors: Hyung-Sik Kang, Eun-Mi Kim, Dong-Hern Kim, Ha-Rim Choi, Eun-Hee Lee, Il-Soo Kim, Chang-Eon Park
  • Patent number: 8252586
    Abstract: This invention provides a system for efficiently producing differentiated cells from pluripotent cells, such as human embryonic stem cells. Rather than permitting the cells to form embryoid bodies according to established techniques, differentiation is effected directly in monolayer culture on a suitable solid surface. The cells are either plated directly onto a differentiation-promoting surface, or grown initially on the solid surface in the absence of feeder cells and then exchanged into a medium that assists in the differentiation process. The solid surface and the culture medium can be chosen to direct differentiation down a particular pathway, generating a cell population that is remarkably uniform. The methodology is well adapted to bulk production of committed precursor and terminally differentiated cells for use in drug screening or regenerative medicine.
    Type: Grant
    Filed: June 3, 2009
    Date of Patent: August 28, 2012
    Assignee: Geron Corporation
    Inventors: Melissa K. Carpenter, R. Scott Thies
  • Patent number: 8252585
    Abstract: This invention provides populations of neural progenitor cells, differentiated neurons, glial cells, and astrocytes. The populations are obtained by culturing stem cell populations (such as embryonic stem cells) in a cocktail of growth conditions that initiates differentiation, and establishes the neural progenitor population. The progenitors can be further differentiated in culture into a variety of different neural phenotypes, including dopaminergic neurons. The differentiated cell populations or the neural progenitors can be generated in large quantities for use in drug screening and the treatment of neurological disorders.
    Type: Grant
    Filed: December 11, 2008
    Date of Patent: August 28, 2012
    Assignee: Geron Corporation
    Inventor: Melissa K. Carpenter
  • Patent number: 8247385
    Abstract: Provided herein are compositions and methods for treating and/or preventing neurodegenerative disease, such as Alzheimer's disease. In particular aspects, compositions administered herein encode a cellular immune response element. The compositions may be prepared and administered in such a manner that the cellular immune response element coding sequence is expressed in the subject to which the composition is administered. The compositions include expression systems, delivery systems, and certain cellular immune response element genes.
    Type: Grant
    Filed: February 4, 2008
    Date of Patent: August 21, 2012
    Inventor: Tai June Yoo
  • Patent number: 8236563
    Abstract: The present invention provides a method of differentiating progenitor cells to produce a population containing protected neuronal cells. A method of the invention includes the steps of contacting the progenitor cells with a differentiating agent; and introducing into the progenitor cells a nucleic acid molecule encoding a MEF2 polypeptide or an active fragment thereof, thereby differentiating the progenitor cells to produce a population containing protected neuronal cells. In one embodiment, the MEF2 polypeptide is human MEF2C or an active fragment thereof.
    Type: Grant
    Filed: March 31, 2011
    Date of Patent: August 7, 2012
    Assignee: Sanford-Burnham Medical Research Institute
    Inventors: Stuart A Lipton, Shu-ichi Okamoto
  • Patent number: 8232100
    Abstract: Disclosed are embryonic stem cell-derived dendritic cells, genetically modified immature dendritic cells capable of maturation, as well as methods for the production of such cells. In one embodiment, the cells made be produced by a method comprising the steps of providing a population of embryonic stem cells; culturing the embryonic stem cells in the presence of a cytokine or combination of cytokines which brings about differentiation of the embryonic stem cells into dendritic cells; and recovering the dendritic cells from the culture. In a further embodiment, the cells may be genetically modified.
    Type: Grant
    Filed: July 21, 2010
    Date of Patent: July 31, 2012
    Assignee: Isis Innovation Limited
    Inventors: Herman Waldmann, Paul J. Fairchild, Richard Gardner, Frances Brook
  • Patent number: 8227246
    Abstract: This invention provides an isolated disc stem cell population, compositions, and methods of obtaining and growing the same. Moreover, this invention provides an isolated discosphere, compositions, and methods of obtaining and growing the same. An artificial disc containing the cells of the present invention is provided together with methods of making the same. This invention also provides a method of treating a subject having a herniated disc utilizing the cells and methods of the invention.
    Type: Grant
    Filed: July 7, 2008
    Date of Patent: July 24, 2012
    Assignee: Discgenics
    Inventors: Valery Kukekeov, Christopher Duntsch, Tatyana Igantova
  • Patent number: 8206699
    Abstract: One form of the present invention is directed to a method of remyelinating demyelinated axons by treating the demyelinated axons with oligodendrocyte progenitor cells under conditions which permit remyelination of the axons. Another aspect of the present invention relates to a method of treating a subject having a condition mediated by a loss of myelin or a loss of oligodendrocytes by administering to the subject oligodendrocyte progenitor cells under conditions effective to treat the condition mediated by a loss of myelin or a loss of oligodendrocytes. A further aspect of the present invention relates to an in vitro method of identifying and separating oligodendrocyte progenitor cells from a mixed population containing other mammalian brain or spinal cord cell types. This further aspect of the present invention involves removing neurons and neuronal progenitor cells from the mixed population to produce a treated mixed population.
    Type: Grant
    Filed: April 29, 2008
    Date of Patent: June 26, 2012
    Assignee: Cornell Research Foundation, Inc.
    Inventors: Steven A. Goldman, Neeta Singh Roy, Martha Windrem
  • Patent number: 8187586
    Abstract: Methods of inducing apoptosis in hyperproliferative cells, particularly cancer cells are provided. Such method involves increasing the levels of a potassium channel modulatory protein in the cell. Examples of such proteins are native KChAP protein, a biologically active variant of native KChAP protein, or a biologically active KChAP-related protein (collectively referred to hereinafter as “KChAP protein”). In one embodiment, the cells are contacted with the KChAP protein under conditions permitting uptake of the protein by the cells. In another embodiment, the cells are contacted with (i) a nucleic acid encoding the KChAP protein, and (ii) a promoter active in the cancer cell, wherein the promoter is operably linked to the region encoding the KChAP protein, under conditions permitting the uptake of the nucleic acid by the cancer cell. Methods of detecting cancerous cells in a biological sample selected from the group consisting of a colorectal tissue sample or brain tissue sample are also provided.
    Type: Grant
    Filed: February 23, 2004
    Date of Patent: May 29, 2012
    Assignee: Case Western Reserve University
    Inventors: Arthur M. Brown, Barbara A. Wible